ClinicalTrials.gg
CompletedNCT03117049Updated May 6, 2024Results posted

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52)

A Phase 3 interventional study of ONO-4538 and Carboplatin in Non-Small Cell Lung Cancer, sponsored by Ono Pharmaceutical Co. Ltd. Completed at 135 sites in 3 countries. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-05-06.

Sponsored by Ono Pharmaceutical Co. Ltd · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 44 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
11th of 120
550 · median 66
Started
2017
with 23 others
Phase 3
24 of 120
3 open now
Registered
44th of 120
by date
Lead sponsor
3 of 120
Ono Pharmaceutical Co. Ltd

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 11th largest by enrollment, is one of 24 that started in 2017, is one of 24 in phase 3, and was the 44th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-naïve subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation in a multicenter, randomized, double-blind study.

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with - or cytologically-confirmed non-squamous non-small cell lung cancer
  • Subjects who received a diagnosis of stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation according to the UICC-TNM Classification (7th edition) with no prior systemic anticancer therapy
  • Subjects with at least one by radiographic tumor assessments per 1.1 criteria
  • Subjects who are able to provide tumor tissue specimens.
  • (ECOG) Performance Status (PS) score of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Subjects with known EGFR mutations, including deletions in exon 19 and exon 21 (L858R) substitution mutations.
  • Subjects with known ALK translocations.
  • Complication or history of severe reactions to antibody products or platinum-containing compounds
  • Subjects with disease or known chronic or recurrent autoimmune disease.
  • Subjects with multiple cancer.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (actual)

Study arms

  • Experimental
    ONO-4538 group

    ONO-4538: 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

    Drug: ONO-4538 · Drug: Carboplatin · Drug: Paclitaxel · Drug: Bevacizumab

  • Placebo comparator
    Placebo group

    Placebo: Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Chemotherapy: Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent. Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

    Drug: Carboplatin · Drug: Paclitaxel · Drug: Bevacizumab · Drug: Placebo

Interventions

  • 360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

  • Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

  • Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

  • Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

  • DrugPlacebo

    Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC)

    PFS (as assessed by the IRRC) will be calculated using the following formula : PFS (days) = "date when overall response is assessed as progressive disease (PD) or date of death (for any reason), whichever comes first" - "date of randomization" + 1. Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.

    Time frame: Approximately 32 months

Secondary outcomes

  1. Overall Survival (OS)

    Time frame: Approximately 32 months

  2. Objective Response Rate (ORR [as Assessed by the IRRC])

    ORR represents the proportion of subjects whose best overall response was assessed as complete response (CR) or partial response (PR). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.

    Time frame: Approximately 32 months

  3. Disease Control Rate (DCR [as Assessed by the IRRC])

    DCR represents the proportion of subjects whose best overall response was assessed as CR, PR, or stable disease (SD). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.

    Time frame: Approximately 32 months

  4. Duration of Response (DOR [as Assessed by the IRRC])

    The lower and upper limits of 95% CI for the median are censored value in the both groups.

    Time frame: Approximately 32 months

  5. Best Overall Response (BOR [as Assessed by the IRRC])

    Time frame: Approximately 32 months

07

Results

Posted Apr 26, 2022

Participant flow

Participant flow — Overall Study
MilestoneONO-4538 GroupPlacebo Group
Started275275
Completed7444
Not completed201231
Withdrew: Continued the follow-up period109129
Withdrew: Died8293
Withdrew: Consent withdrawal76
Withdrew: Missing contact33

Outcome measures

PrimaryProgression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC)

PFS (as assessed by the IRRC) will be calculated using the following formula : PFS (days) = "date when overall response is assessed as progressive disease (PD) or date of death (for any reason), whichever comes first" - "date of randomization" + 1. Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.

Time frame:
Approximately 32 months
Reported as:
Median · months
Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC)
monthsONO-4538 GroupPlacebo Group
Progression Free Survival (PFS) as Assessed by the Independent Radiology Review Committee (IRRC)12.1 (9.8 to 14.0)8.1 (7.0 to 8.5)
Statistical analysis
  • ONO-4538 Group vs Placebo Group · Stratified log-rank test · p = <0.0001 · Hazard ratio (hr): 0.56 · 96.37% CI 0.43 to 0.71
SecondaryOverall Survival (OS)
Time frame:
Approximately 32 months
Reported as:
Median · months
Overall Survival (OS)
monthsONO-4538 GroupPlacebo Group
Overall Survival (OS)25.4 (21.8 to NA)24.7 (20.2 to NA)
Statistical analysis
  • ONO-4538 Group vs Placebo Group · Stratified hazard ratio: 0.85 · 95% CI 0.63 to 1.14
SecondaryObjective Response Rate (ORR [as Assessed by the IRRC])

ORR represents the proportion of subjects whose best overall response was assessed as complete response (CR) or partial response (PR). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.

Time frame:
Approximately 32 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR [as Assessed by the IRRC])
percentage of participantsONO-4538 GroupPlacebo Group
Objective Response Rate (ORR [as Assessed by the IRRC])61.5 (55.4 to 67.2)50.5 (44.5 to 56.6)
Statistical analysis
  • ONO-4538 Group vs Placebo Group · Odds ratio (or): 1.55 · 95% CI 1.11 to 2.17
SecondaryDisease Control Rate (DCR [as Assessed by the IRRC])

DCR represents the proportion of subjects whose best overall response was assessed as CR, PR, or stable disease (SD). Please refer to the protocol, in this study, tumor response will be evaluated by CT, etc. according to the RECIST 1.1 criteria.

Time frame:
Approximately 32 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR [as Assessed by the IRRC])
percentage of participantsONO-4538 GroupPlacebo Group
Disease Control Rate (DCR [as Assessed by the IRRC])87.3 (82.7 to 91.0)89.8 (85.6 to 93.1)
Statistical analysis
  • ONO-4538 Group vs Placebo Group · Odds ratio (or): 0.77 · 95% CI 0.46 to 1.31
SecondaryDuration of Response (DOR [as Assessed by the IRRC])

The lower and upper limits of 95% CI for the median are censored value in the both groups.

Time frame:
Approximately 32 months
Reported as:
Median · months
Duration of Response (DOR [as Assessed by the IRRC])
monthsONO-4538 GroupPlacebo Group
Duration of Response (DOR [as Assessed by the IRRC])11.0 (1.1 to 25.8)7.0 (1.2 to 26.0)
SecondaryBest Overall Response (BOR [as Assessed by the IRRC])
Time frame:
Approximately 32 months
Reported as:
Count of participants · Participants
Best Overall Response (BOR [as Assessed by the IRRC])
ParticipantsONO-4538 GroupPlacebo Group
Complete response148
Partial response155131
Stable disease71108
Progressive disease511
Not evaluable3017

Adverse events

Collected over For each randomised subject, adverse events(AEs) were collected from the start date of administration of the investigational product to 30 days after the last dose of any of the study treatment (The maximum was about 30 months). Drug-related AEs or AEs leading to discontinuation reported at the start of follow-up should be investigated at appropriate intervals until no further follow-up is required because the events have resolved or are resolving, or the symptoms become stable.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ONO-4538 Group82/275 (29.8%)154/273 (56.4%)271/273 (99.3%)
Placebo Group93/275 (33.8%)118/275 (42.9%)274/275 (99.6%)
Most frequent serious events
Showing 10 of 186
Most frequent serious events
EventONO-4538 GroupPlacebo Group
Febrile neutropeniaBlood and lymphatic system disorders27/27312/275
PneumoniaInfections and infestations21/27315/275
PyrexiaGeneral disorders16/2734/275
PneumonitisRespiratory, thoracic and mediastinal disorders9/2730/275
ColitisGastrointestinal disorders8/2731/275
PneumothoraxRespiratory, thoracic and mediastinal disorders8/2735/275
Decreased appetiteMetabolism and nutrition disorders5/2738/275
Adrenal insufficiencyEndocrine disorders7/2731/275
Neutrophil count decreasedInvestigations6/2730/275
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders6/2733/275
Most frequent other events
Showing 10 of 115
Most frequent other events
EventONO-4538 GroupPlacebo Group
ConstipationGastrointestinal disorders150/273134/275
AlopeciaSkin and subcutaneous tissue disorders143/273150/275
Neutrophil count decreasedInvestigations117/273141/275
Peripheral sensory neuropathyNervous system disorders121/273116/275
Decreased appetiteMetabolism and nutrition disorders98/273108/275
AnaemiaBlood and lymphatic system disorders88/273102/275
NauseaGastrointestinal disorders86/273100/275
White blood cell count decreasedInvestigations94/27399/275
RashSkin and subcutaneous tissue disorders96/27348/275
MyalgiaMusculoskeletal and connective tissue disorders76/27392/275

Baseline characteristics

Age, Continuous
Age, Continuous(years)ONO-4538 GroupPlacebo GroupTotal
Median66 (27 to 85)66 (33 to 83)66 (27 to 85)
Age, Customized
Age, Customized(Participants)ONO-4538 GroupPlacebo GroupTotal
<65 years131111242
65-74 years117131248
>=75 years273360
Sex: Female, Male
Sex: Female, Male(Participants)ONO-4538 GroupPlacebo GroupTotal
Female7069139
Male205206411
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ONO-4538 GroupPlacebo GroupTotal
American Indian or Alaska Native000
Asian275275550
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Country
Country(Participants)ONO-4538 GroupPlacebo GroupTotal
Japan188183371
Korea6263125
Taiwan252954
ECOG Performance Score
ECOG Performance Score(Participants)ONO-4538 GroupPlacebo GroupTotal
0129128257
1146147293
Smoking status
Smoking status(Participants)ONO-4538 GroupPlacebo GroupTotal
Never6154115
Current182139
Former196200396
Staging (the UICC-TNM classification, 7th edition)
Staging (the UICC-TNM classification, 7th edition)(Participants)ONO-4538 GroupPlacebo GroupTotal
Stage IIIB151429
Stage IV239238477
Recurrent212344

2 further baseline measures are reported on the registry.

08

Study locations

135 sites
  • Aichi Clinical Site2
    Nagoya, Aichi, Japan
  • Aichi Clinical Site3
    Nagoya, Aichi, Japan
  • Aichi Clinical Site4
    Nagoya, Aichi, Japan
  • Aichi Clinical Site
    Nagoya, Aichi, Japan
  • Aichi Clinical Site
    Toyoake, Aichi, Japan
  • Aomori Clinical Site2
    Hirosaki, Aomori, Japan
  • Aomori Clinical Site
    Hirosaki, Aomori, Japan
  • Chiba Clinical Site
    Yachiyo, Chiba, Japan
  • Ehime Clinical Site
    Matsuyama, Ehime, Japan
  • Fukuoka Clinical Site
    Iizuka, Fukuoka, Japan
  • Fukuoka Clinical Site
    Kitakyushu, Fukuoka, Japan
  • Fukuoka Clinical Site
    Koga, Fukuoka, Japan
  • Fukuoka Clinical Site
    Kurume, Fukuoka, Japan
  • Fukushima Clinical Site
    Kōriyama, Fukushima, Japan
  • Gunma Clinical Site
    Ota, Gunma, Japan
  • Gunma Clinical Site
    Shibukawa, Gunma, Japan
  • Hokkaido Clinical Site
    Asahikawa, Hokkaido, Japan
  • Hokkaido Clinical Site2
    Sapporo, Hokkaido, Japan
  • Hokkaido Clinical Site
    Sapporo, Hokkaido, Japan
  • Hyogo Clinical Site
    Akashi, Hyogo, Japan
  • Hyogo Clinical Site
    Amagasaki, Hyogo, Japan
  • Hyogo Clinical Site
    Himeji, Hyogo, Japan
  • Hyogo Clinical Site
    Itami, Hyogo, Japan
  • Hyogo Clinical Site
    Kobe, Hyogo, Japan
  • Hyogo Clinical Site
    Nishinomiya, Hyogo, Japan
  • Hyogo Clinical Site
    Takarazuka, Hyogo, Japan
  • Ibaraki Clinical Site
    Higashiibaraki, Ibaraki, Japan
  • Ibaraki Clinical Site
    Kasama, Ibaraki, Japan
  • Ibaraki Clinical Site
    Tsuchiura, Ibaraki, Japan
  • Ishikawa Clinical Site2
    Kanazawa, Ishikawa, Japan
  • Ishikawa Clinical Site3
    Kanazawa, Ishikawa, Japan
  • Ishikawa Clinical Site
    Kanazawa, Ishikawa, Japan
  • Iwate Clinical Site
    Morioka, Iwate, Japan
  • Kanagawa Clinical Site
    Isehara, Kanagawa, Japan
  • Kanagawa Clinical Site2
    Kawasaki, Kanagawa, Japan
  • Kanagawa Clinical Site
    Kawasaki, Kanagawa, Japan
  • Kanagawa Clinical Site
    Sagamihara, Kanagawa, Japan
  • Kanagawa Clinical Site2
    Yokohama, Kanagawa, Japan
  • Kanagawa Clinical Site3
    Yokohama, Kanagawa, Japan
  • Kanagawa Clinical Site
    Yokohama, Kanagawa, Japan
  • Kumamoto Clinical Site
    Koshi, Kumamoto, Japan
  • Kyoto Clinical Site
    Jōyō, Kyoto, Japan
  • Mie Clinical Site
    Tsu, Mie, Japan
  • Miyagi Clinical Site
    Natori, Miyagi, Japan
  • Miyagi Clinical Site
    Sendai, Miyagi, Japan
  • Nagano Clinical Site
    Matsumoto, Nagano, Japan
  • Nagasaki Clinical Site
    Ōmura, Nagasaki, Japan
  • Nara Clinical Site
    Ikoma, Nara, Japan
  • Niigata Clinical Site
    Nagaoka, Niigata, Japan
  • Oita Clinical Site
    Beppu, Oita, Japan
  • Oita Clinical Site
    Yufu, Oita, Japan
  • Osaka Clinical Site2
    Osaka, Osaka Clinical Site, Japan
  • Osaka Clinical Site
    Habikino, Osaka, Japan
  • Osaka Clinical Site
    Hirakata, Osaka, Japan
  • Osaka Clinical Site
    Kishiwada, Osaka, Japan
  • Osaka Clinical Site
    Osakasayama, Osaka, Japan
  • Osaka Clinical Site
    Sakai, Osaka, Japan
  • Osaka Clinical Site
    Toyonaka, Osaka, Japan
  • Saga Clinical Site
    Ureshino, Saga, Japan
  • Saitama Clinical Site
    Hidaka, Saitama, Japan
  • Saitama Clinical Site
    Kitaadachi-gun, Saitama, Japan
  • Shimane Clinical Site
    Izumo, Shimane, Japan
  • Shizuoka Clinical Site
    Hamamatsu, Shizuoka, Japan
  • Shizuoka Clinical Site
    Sunto-gun, Shizuoka, Japan
  • Tokyo Clinical Site2
    Bunkyo-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Bunkyo-ku, Tokyo, Japan
  • Tokyo Clinical Site2
    Bunkyō-Ku, Tokyo, Japan
  • Tokyo Clinical Site2
    Chuo-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Chuo-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Fuchū, Tokyo, Japan
  • Tokyo Clinical Site
    Itabashi-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Kiyose, Tokyo, Japan
  • Tokyo Clinical Site
    Koto-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Meguro, Tokyo, Japan
  • Tokyo Clinical Site
    Minato-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Mitaka-shi, Tokyo, Japan
  • Tokyo Clinical Site
    Shibuya, Tokyo, Japan
  • Tokyo Clinical Site2
    Shinjuku-Ku, Tokyo, Japan
  • Tokyo Clinical Site3
    Shinjuku-Ku, Tokyo, Japan
  • Tokyo Clinical Site
    Shinjuku-ku, Tokyo, Japan
  • Tokyo Clinical Site
    Tachikawa, Tokyo, Japan
  • Tottori Clinical Site
    Yonago, Tottori, Japan
  • Yamaguchi Clinical Site
    Iwakuni, Yamaguchi, Japan
  • Chiba Clinical Site2
    Chiba, Japan
  • Chiba Clinical Site
    Chiba, Japan
  • Fukui Clinical Site
    Fukui, Japan
  • Fukuoka Clinical Site2
    Fukuoka, Japan
  • Fukuoka Clinical Site3
    Fukuoka, Japan
  • Fukuoka Clinical Site4
    Fukuoka, Japan
  • Fukuoka Clinical Site
    Fukuoka, Japan
  • Gifu Clinical Site2
    Gifu, Japan
  • Gifu Clinical Site
    Gifu, Japan
  • Hiroshima Clinical Site2
    Hiroshima, Japan
  • Hiroshima Clinical Site
    Hiroshima, Japan
  • Kochi Clinical Site
    Kochi, Japan
  • Kumamoto Clinical Site
    Kumamoto, Japan
  • Kyoto Clinical Site
    Kyoto, Japan
  • Nagasaki Clinical Site
    Nagasaki, Japan
  • Niigata Clinical Site2
    Niigata, Japan
  • Niigata Clinical Site
    Niigata, Japan

Showing the first 100 of 135 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Feb 2020, 31 months.

Results were first posted in Apr 2022, 2 years 2 months after primary completion.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 31 months is below that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2017
First posted
Apr 17, 2017
StartActual
Jun 13, 2017
Primary completionActual
Feb 10, 2020
CompletionActual
Dec 4, 2023
Results first posted
Apr 26, 2022
Last update
May 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03117049
Responsible party
Sponsor
First posted
Apr 17, 2017
Start date
Jun 13, 2017
Primary completion
Feb 10, 2020
Completion
Dec 4, 2023
Results posted
Apr 26, 2022
Last update
May 6, 2024

Study contacts

Shigeru Takahashi
study director · Ono Pharmaceutical Co. Ltd

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion